Evidence map›Paper›PMID 39930469›Full record

ArticleJournal of experimental & clinical cancer research : CR2025

ELK3-CYFIP2 axis-mediated actin remodeling modulates metastasis and natural killer cell responses in triple-negative breast cancer.

Seung Hee Choi, Hye Jung Jang, Joo Dong Park, Ki Seo Ryu, Eunchong Maeng, Seohyun Cho, Hail Park, Hae-Yun Jung, Kyung-Soon Park

Erratum issuedAbstract read
In one paragraph

Article in Journal of experimental & clinical cancer research : CR, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. A multi-omics dissection of INHBAJournal of translational medicine · 2026
    Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors.

Seung Hee ChoiDepartment of Biomedical Science, CHA University, Seongnam, Republic of Korea.
Hye Jung JangDepartment of Integrative Biotechnology, Sungkyunkwan University, Suwon, Republic of Korea.
Joo Dong ParkDepartment of Integrative Biotechnology, Sungkyunkwan University, Suwon, Republic of Korea.
Ki Seo RyuDepartment of Biomedical Science, CHA University, Seongnam, Republic of Korea.
Eunchong MaengDepartment of Biomedical Science, CHA University, Seongnam, Republic of Korea.
Seohyun ChoDepartment of Biomedical Science, CHA University, Seongnam, Republic of Korea.
Hail ParkDepartment of Biomedical Science, CHA University, Seongnam, Republic of Korea.
Hae-Yun JungDivision of Radiation Biomedical Research, Korea Institute of Radiological and Medical Sciences, Seoul, Republic of Korea.
Kyung-Soon ParkDepartment of Biomedical Science, CHA University, Seongnam, Republic of Korea. kspark@cha.ac.kr.

Funding

Korea Institute of Radiological and Medical Sciences 50531-2024National Institute for International Education 2019R1A6A1A03032888, NRF-2022R1A2C1003390National Institute for International Education RS-2023-00271041
6 · The paper itself

Abstract

Triple-negative breast cancer (TNBC) is an aggressive, highly metastatic disease with a poor prognosis. E26 transformation-specific transcription factor (ELK3) is highly expressed in TNBCs, and functions as a regulator of epithelial-mesenchymal transition and immune responses. Because metastatic migration and immune evasion by TNBC cells are critical factors for successful metastasis, unravelling the underlying mechanisms and developing effective immunotherapeutic strategies is urgent. Here, TNBC cell lines MDA-MB-231 and Hs578T were examined to determine the relationship between ELK3 expression and filopodia protrusion on the cell membrane, as well as actin accumulation at contact sites with natural killer (NK) cells. RNA-sequencing analysis and molecular experiments were conducted to identify and validate downstream target genes of ELK3 associated with migration and attachment of TNBC cells. The immune response of TNBC to NK cells was evaluated through imaging and flow cytometry analyses. Clinical significance was assessed through Kaplan-Meier analysis of survival outcomes of TNBC patients. Gene expression profiling and molecular analysis revealed that oncogenic ELK3 directly suppresses expression of cytoplasmic FMR1 interacting protein2 (CYFIP2), a repressor of actin accumulation. Further molecular and pharmacological analyses confirmed that the ELK3-CYFIP2 axis serves a dual role in TNBC cell lines by (1) controlling filopodia-mediated migration and adhesion by regulating actin accumulation, and (2) regulating sensitivity to NK cells by modulating actin accumulation at contact sites. Kaplan-Meier analysis suggested that ELK3-CYFIP2 axis is associated with survival of TNBC patients, and that ELK3 suppresses transcription of CYFIP2. Thus, the ELK3-CYFIP2 axis plays a pivotal role in regulating actin, emphasizing its significance in controlling both cancer cell migration and NK cell responses in TNBC.

Indexed as

ActinsAdaptor Proteins, Signal TransducingKiller Cells, NaturalProto-Oncogene Proteins c-etsTriple Negative Breast NeoplasmsCell Line, TumorCell MovementFemaleGene Expression Regulation, NeoplasticHumansNeoplasm MetastasisPrognosisActinsAdaptor Proteins, Signal TransducingElk3 protein, humanProto-Oncogene Proteins c-etsActin accumulationCYFIP2ELK3FilopodiaNatural killer cellTriple-negative breast cancer

Identifiers

PMID39930469
PMCPMC11808954

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.